Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.
about
Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative reviewNanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionLiquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma.Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients.Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation.Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.Dolutegravir/rilpivirine for the treatment of HIV-1 infection
P2860
Q26783160-7EC59E58-88EE-4057-ACA9-F41BB9377E90Q27318354-15F12813-DD90-4194-9DCC-19727C00232DQ34316101-417DE524-5269-4F73-9A9E-F133CD847264Q35547048-86FA53FC-1A81-437C-9DE6-03FD11ECE235Q35760170-54304B32-CBC3-464F-A35E-D85DAC2E96E5Q37710424-207ACA81-9C51-4417-AEDB-A39C2C2C6BCFQ38601891-B198B9A4-680D-4E52-A37C-EF672282422AQ47301806-56C9EE80-9DBB-404E-92FF-4DC3A9A5930BQ49228013-585E97D4-AF32-4CD6-8029-E8AEA14BA3FBQ50494692-310DD8B2-0B5D-4870-B242-6C343EFF40D7Q53696849-DA2FE10A-80FC-45E0-B09A-D9B56E4267F2Q59135153-9BC6DF81-B0A6-40D6-B068-565247D81038
P2860
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Safety, efficacy, and pharmaco ...... on resource-limited settings.
@ast
Safety, efficacy, and pharmaco ...... on resource-limited settings.
@en
type
label
Safety, efficacy, and pharmaco ...... on resource-limited settings.
@ast
Safety, efficacy, and pharmaco ...... on resource-limited settings.
@en
prefLabel
Safety, efficacy, and pharmaco ...... on resource-limited settings.
@ast
Safety, efficacy, and pharmaco ...... on resource-limited settings.
@en
P2093
P2860
P356
P1476
Safety, efficacy, and pharmaco ...... on resource-limited settings.
@en
P2093
Isabelle Andrieux-Meyer
Janice Lee
Nathan Ford
P2860
P356
10.2147/HIV.S14559
P407
P577
2011-04-28T00:00:00Z